Researchers found that lubiprostone, a drug typically used to treat constipation, may also help protect kidney function in people with chronic kidney disease (CKD). In a clinical trial involving 150 patients, those taking lubiprostone experienced a slower decline in kidney function compared to those receiving a placebo. This finding is significant because CKD affects millions globally and often leads to dialysis. If lubiprostone can help maintain kidney health, it could improve the quality of life for many individuals facing this condition.

The study revealed that lubiprostone might work by altering gut bacteria, which in turn boosts the production of spermidine, a compound linked to healthier cellular energy production. This connection suggests that improving gut health could be a new avenue for protecting the kidneys. The trial measured kidney performance using a standard indicator known as estimated glomerular filtration rate (eGFR), and results indicated that higher doses of lubiprostone led to greater benefits in preserving kidney function.

While these results are promising, they come from an early-stage clinical trial, meaning more research is needed to confirm the findings in larger populations. Researchers are planning further trials to validate the benefits and explore which patients might respond best to treatment. Although lubiprostone is already an approved medication, its potential use for kidney protection could pave the way for new treatment strategies for CKD and possibly other chronic diseases linked to mitochondrial dysfunction.

Source: sciencedaily.com